NCT05164016
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: up to 24 Years (Child, Adult))
Location of Metastases: 
Additional Notes: 
Exclusions: Patients older than 24 years of age
https://ClinicalTrials.gov/show/NCT05164016